Book contents
- Frontmatter
- Contents
- Tables
- Figures
- About the Editors
- Contributors
- Preface
- Acknowledgments
- Foreword
- Introduction: Charting a Sustainable Path for the Twenty-First Century Pharmaceutical Industry
- PART I PROFITS, PATIENTS' RIGHTS, AND SCIENTIFIC PROGRESS: THE ETHICS OF CLINICAL RESEARCH CONDUCTED IN PRIVATE ENTERPRISES
- PART II MARKETING AND THE EFFICIENT UTILIZATION OF HEALTHCARE RESOURCES: ETHICAL AND PUBLIC POLICY CHALLENGES
- PART III PATENTS, PRICING, AND EQUAL ACCESS
- Introduction to Part III
- 15 Intellectual Property Rights, Access to Life-Enhancing Drugs, and Corporate Moral Responsibilities
- 16 A Future Agenda for Government–Industry Relations
- 17 AIDS Activism and the Pharmaceutical Industry
- 18 The Campaign Against Innovation
- 19 Third World Perspectives on Global Pharmaceutical Access
- 20 The Promise of Vaccines and the Influenza Vaccine Shortage of 2004: Public and Private Partnerships
- PART IV CONCLUDING THOUGHTS: CHARTING A SUSTAINABLE PATH FOR THE TWENTY-FIRST CENTURY
- Notes
- Index
18 - The Campaign Against Innovation
Published online by Cambridge University Press: 04 December 2009
- Frontmatter
- Contents
- Tables
- Figures
- About the Editors
- Contributors
- Preface
- Acknowledgments
- Foreword
- Introduction: Charting a Sustainable Path for the Twenty-First Century Pharmaceutical Industry
- PART I PROFITS, PATIENTS' RIGHTS, AND SCIENTIFIC PROGRESS: THE ETHICS OF CLINICAL RESEARCH CONDUCTED IN PRIVATE ENTERPRISES
- PART II MARKETING AND THE EFFICIENT UTILIZATION OF HEALTHCARE RESOURCES: ETHICAL AND PUBLIC POLICY CHALLENGES
- PART III PATENTS, PRICING, AND EQUAL ACCESS
- Introduction to Part III
- 15 Intellectual Property Rights, Access to Life-Enhancing Drugs, and Corporate Moral Responsibilities
- 16 A Future Agenda for Government–Industry Relations
- 17 AIDS Activism and the Pharmaceutical Industry
- 18 The Campaign Against Innovation
- 19 Third World Perspectives on Global Pharmaceutical Access
- 20 The Promise of Vaccines and the Influenza Vaccine Shortage of 2004: Public and Private Partnerships
- PART IV CONCLUDING THOUGHTS: CHARTING A SUSTAINABLE PATH FOR THE TWENTY-FIRST CENTURY
- Notes
- Index
Summary
The issues I'll address in this chapter – basically, the tension between society's desire for better medicine and its aversion to higher healthcare costs – may be familiar. But I hope to offer an angle of view on these issues that may not be so familiar. I want you to look over my shoulder and see how the various choices in the policy environment affect the choices available to a CEO in my industry.
Let me start with a question: Do you believe we already have all the medical innovation we need? That may sound like a purely rhetorical question, but it's not. For one thing, there are some influential commentators who are on record as saying, in essence, “yes.” If actions can be taken as answers, I have to assume that many policymakers, here and in other nations, must agree with that view.
The two most important preconditions for innovation in my industry are market-based pricing and intellectual property protection. But when I look at healthcare systems around the world, I see that policies that support innovation are dwindling, whereas policies that discourage it are proliferating. A third-party observer trying to make sense of this, without access to other data on the motives involved, might reasonably conclude that this amounts to a worldwide campaign against pharmaceutical innovation.
These measures are almost always advocated and adopted in the name of cost control.
- Type
- Chapter
- Information
- Ethics and the Pharmaceutical Industry , pp. 326 - 335Publisher: Cambridge University PressPrint publication year: 2005
- 2
- Cited by